Research Article

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany

Figure 5

Treatment response from baseline to 12 and 24 months for patients receiving ≤4 OCT or ≥8 OCT examinations for the matched sample (N = 411 for both groups). BCVA: best-corrected visual acuity; OCT: optical coherence tomography. (a) 12 months; (b) 24 months.
(a)
(b)